High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy

Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery

(2020) Changhui Li et al.   LUNG CANCER

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

(2018) Nathan A. Pennell et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

(2017) Misako Nagasaka et al.   Expert Review of Anticancer Therapy

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

(2017) Emily Castellanos et al.   Journal of Thoracic Oncology

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma

(2016) Tomoharu Yoshiya et al.   ANNALS OF THORACIC SURGERY

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

(2015) R. Govindan et al.   CLINICAL CANCER RESEARCH

Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma

(2015) C.–h. Xu et al.   EJSO

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival

(2014) Jung-Jyh Hung et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients

(2014) Liu Chao et al.   LUNG CANCER

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

(2014) Yan Sun et al.   World Journal of Surgical Oncology

Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype: a retrospective analysis of Japanese lung cancer registry data

(2013) H. Sakurai et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller

(2013) Jun-ichi Nitadori et al.   JNCI-Journal of the National Cancer Institute

New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma

(2013) Naoki Yanagawa et al.   Journal of Thoracic Oncology

Subtyping Lung Adenocarcinoma According to the Novel 2011 IASLC/ATS/ERS Classification

(2013) Morihito Okada   Thoracic Surgery Clinics

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

(2012) Y. Zhang et al.   CLINICAL CANCER RESEARCH

The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

(2012) Arne Warth et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification

(2011) Hyo Sup Shim et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

(2011) Akihiko Yoshizawa et al.   MODERN PATHOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY